the bar inches a little higher, page-8

Go up 1400%? IF Solbec can repeat what they saw on the RCC patient in the phase1/2 trial, then I would say at least a 14 bagger. As you have seen there is no really effective treatment for late stage RCC, and an effective drug would be rushed to market, as they did with Pfizer's Sutent.
Why the big difference in market cap? All of the risk is gone from Onyx with an approved drug. To further diminish the risk they have a big powerful partner in Bayer to help with marketing and further development. They have the results on the board. Solbec needs to complete the phase 2 to demonstrate Coramsines efficacy IMHO.